Overall, there was no difference in patient burden of comorbidities, preoperative albumin, peritoneal cancer index score, completion of cytoreduction, estimated blood loss, length of surgery, tumor grade/differentiation, and hospital length of stay across all BMI subgroups. This evidence concerns the gene ALB and peritoneum cancer.